Intelligence · Patents
Patents expiring in 2044
Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.
- Patents
- 1,766
Quick answer
1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12157891
Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors
granted -
US 12156870
Antibody drug conjugates comprising sting agonists
granted -
US 12157743
Solid forms of Alpha-1062 gluconate
granted -
US 12156914
Pharmaceutical compositions comprising bupropion and cysteine
granted -
US 12156908
Virus like nanoparticle compositions and methods thereof
granted -
US 12156912
Methods and compositions for inhibiting diseases of the central nervous system
granted -
US 12157735
Compounds for targeted degradation of BRD9
granted -
US 12157758
Readily isolated bispecific antibodies with native immunoglobulin format
granted -
US 12157778
Peptides for activation of cell signaling in osteoprogenitor cells
granted -
US 12156883
Bisphosphocin gel formulations and uses thereof
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12157762
Tethered interleukin-15 and interleukin-21
granted -
US 12159700
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
granted -
US 12156940
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12156879
Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy
granted -
US 12156897
Magnesium-containing oxytocin formulations and methods of use
granted -
US 12156893
Oral composition comprising lactic acid bacteria for regulating immune responses and methods related thereto
granted -
US 12156862
Medicaments for the treatment of vasoconstriction related diseases or disorders
granted -
US 12157901
Dendritic cell generator
granted -
US 2024398790
TREATING SPONDYLOARTHRITIC CONDITIONS WITH UPADACITINIB
granted -
WO 2024249235
CONJUGUÉS ANTICORPS-MÉDICAMENT D'AGENT DE DÉGRADATION DE BET ANTI-CD33 HUMAIN
granted -
WO 2024249615
EXOSOMES DE LAIT BOVIN POUR ADMINISTRER DE LA VITAMINE D
granted -
US 12162912
Proteins for blocking neurotransmitter release
granted -
US 12161643
Stable formulations of SHR0302
granted -
US 12161678
Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
granted -
US 12161706
Cancer vaccines targeting BORIS and uses thereof
granted -
US 12162855
Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
granted -
US 12162857
Antiviral compounds
granted -
US 12162853
Synthesis of esuberaprost prodrugs
granted -
US 12161097
Non-human animals having a humanized signal-regulatory protein gene
granted -
US 12161674
CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor cells and uses thereof
granted -
US 12161655
Methods of treating mycobacterial infections using tetracycline compounds
granted -
US 12161733
Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
granted -
US 12162818
Inhibitors of the n-terminal domain of the androgen receptor
granted -
US 12161702
Methods and compositions for CNS delivery of heparan N-sulfatase
granted -
US 12162838
Human plasma kallikrein inhibitors
granted -
US 12162997
Facile assembly of soft nanoarchitectures and co-loading of hydrophilic and hydrophobic molecules via flash nanoprecipitation
granted -
US 12162920
Hinge area and use of same in constructing car skeleton
granted -
US 12162943
High affinity human antibodies to human IL-4 receptor
granted -
US 12163153
Methods of manufacturing allogeneic CAR T cells
granted -
US 12163192
Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereof
granted -
US 12163168
Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
granted -
US 12163148
Directed editing of cellular RNA via nuclear delivery of CRISPR/Cas9
granted -
US 12163169
Inducible chimeric cytokine receptors
granted -
US 12162948
Methods of engineering transferrin receptor binding polypeptides
granted -
US 12162950
Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
granted -
US 12162949
CD38 antibody
granted -
US 12162937
Methods of treating an inflammatory disorder by administering an antibody which binds to a connexin CX43 hemichannel
granted
Frequently asked questions
How many pharma patents expire in 2044?
1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.